Wall Street fecha semana sem rumo. Grandes tecnológicas pressionam

[MatildeSerrano]

Hoje a cair 30%...

Pedro200, não há pump hoje ?

[pedro200]

O CEO da Generex tem opções de compra de 1500000 acções a 0,282!

http://investor.generex.com/secfiling.c ... IK=1059784

Boa semana

[AC Investor Blog]

A procura de acções da GNBT é impressionante. Continuo longo com várias posições desde o anuncio no twitter. Não tenciono sair do papel com este estado de acumulação que estamos assistir. É muito suspeito este tipo de ordens compra, nomeadamente a quantidade.

Um seguidor meu no twitter partilhou comigo esta informação colocada no seu site. http://stocknewsnow.com/?p=2767

Aqui podem ver a possivel revolução que podemos vir assistir neste campo da Medicina.

[pedro200]

AC: podes fazer uma análise técnica à GNBT?

Obrigado

Pedro desculpa o atraso....

Obrigado Ac pelo gráfico! Sempre que possível, tenho acompanhado os teus comentários no twiter sobre a GNBT.

Recordo uma reportagem que saiu recentemente na Bloomberg TV sobre o AE37....
http://www.bloomberg.com/video/83137924/

Boa semana para todos!

[MatildeSerrano]

Pedro, devias dizer que trabalhas na área da Medicina e tens acompanhado esta empresa de perto. Talvez percebem-se melhor a razão pela qual tens uma certa simpatia pela empresa.

Poupa-nos.

[AC Investor Blog]

AC: podes fazer uma análise técnica à GNBT?

Obrigado

Pedro desculpa o atraso....

Como tens visto ando novamente de olho nela sendo umas das minhas favoritas das small bios, e carreguei-a após a quebra do triângulo. Acabei de partilhar este gráfico no twitter á minutos no qual aponto para uma possivel ida aos $.325. Pelo que tenho acompanhado há muito interesse neste papel e o volume recente é revelador disso, se o AE37 começar a ganhar momentum, não sei não... até onde isto pode ir... vamos acompanhando

Pedro, devias dizer que trabalhas na área da Medicina e tens acompanhado esta empresa de perto. Talvez percebem-se melhor a razão pela qual tens uma certa simpatia pela empresa.

[pvg80713]

em breakout mode! (take off)

a subir 20% e já passou dos 20 centimos !
mas atenção ainda... cuidados, caldos de galinha.
pode ser apenas o Dead Cat Bounce...

[pedro200]

em breakout mode! (take off)

[pedro200]

pedro200,
a GNBT continua, como sempre igual.

Olha que não é bem assim. Negoceia acima da MM50 e MM200 e nas ultimas semanas tem tido boas subidas. Alias face ao minimo nos 0.076$ basta fazer as contas e ver quanto já subiu. Já tive estas acções a ~0,35 acabei por vender a ~0,34 acho que também por estar a perder no cambio na altura, mas agora estou a pensar entrar novamente com um valor muito baixo por ser o trade de risco que é e ter 2 projectos principais que se aprovados e eficazes podem catapultar a empresa para outros patamares. pedro200 não ia existir um reverse stock split para a empresa poder entrar numa bolsa americana de maior visibilidade?

Cumprimentos

Sim, O reverse split foi aprovado em assembleia geral e pode ser executado até ao final do ano. Além disso também estão previstos dividendos, na forma de acções da antigen express.

Entretanto, vão saindo noticias sobre o AE37 (prefiro não comentar, já todos sabem a minha opinião)

http://seekingalpha.com/article/318937- ... urce=yahoo

"In the first six months of 2011, Roche reported worldwide sales of Herceptin at $3.5B."

[MVP]

pedro200,
a GNBT continua, como sempre igual.

Olha que não é bem assim. Negoceia acima da MM50 e MM200 e nas ultimas semanas tem tido boas subidas. Alias face ao minimo nos 0.076$ basta fazer as contas e ver quanto já subiu. Já tive estas acções a ~0,35 acabei por vender a ~0,34 acho que também por estar a perder no cambio na altura, mas agora estou a pensar entrar novamente com um valor muito baixo por ser o trade de risco que é e ter 2 projectos principais que se aprovados e eficazes podem catapultar a empresa para outros patamares. pedro200 não ia existir um reverse stock split para a empresa poder entrar numa bolsa americana de maior visibilidade?

Cumprimentos

[pvg80713]

pedro200,

as ultimas mensagens deste tópico são sempre tuas.

a GNBT continua, como sempre igual.

tenho pena que o Sr Ulisses, não te admoeste por postares , post´s teus em cima de post´s teus...

evita.... acho eu.

eu sei que estás muito entalado em GNBT, mas a tua propaganda é negativa.

[pedro200]

AC: podes fazer uma análise técnica à GNBT?

Obrigado

[pedro200]

Curiosidade - Empresa de biotecnologia INHX

Em 2009 cada acção valia 0,22...
Hoje cada acção vale 23,70...

Em 2/3 anos tudo mudou....

http://finance.yahoo.com/echarts?s=INHX ... sma(50,200)+volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

[pedro200]

http://www.thenationonlineng.net/2011/i ... ancer.html

Could this be the end of cancer?

Cancer is a killer disease. For long, it has damaged the world, which has been desperate to find a cure for it. That cure seems to be in sight, reports the American Newsweek magazine in its December 19, 2011 edition.


It's a disease that kills millions a year and a slew of hoped-for miracle treatments have gone nowhere. Now scientists say vaccines could hold the key—not just to a cure but to wiping out cancer forever.

By all rights, Shari Baker should have said her final goodbyes years ago. In 2005, more than a year after three doctors dismissed a lump under her arm as a harmless cyst, she was diagnosed with stage IV (metastatic) breast cancer, which takes the lives of at least 80 per cent of patients within five years; it killed Elizabeth Edwards in 2010. Half of those diagnosed with breast cancer that has spread—in Baker, it had reached her spine—die within 39 months. But the 53-year-old jewelry designer in Scottsdale, Ariz., wasn’t ready to die. “I’ve been a competitive athlete and a body builder, I take care of myself and eat right,” she says. “I was going to fight this.”

Baker began searching for a clinical trial, and through the International Cancer Advocacy Network (ICAN) found an intriguing possibility: a cancer vaccine. In May 2006, she travelled to the University of Washington. The vaccine was injected into her upper arm; she got five more shots over the next five months. Today, with scans detecting no cancer anywhere, Baker seems to have beaten some extremely stiff odds.

Short of a sci-fi nano-camera to capture what was going on at the cellular level, it’s impossible to know exactly what the vaccine did. But based on studies of lab animals and cells in petri dishes, scientists have a pretty good idea. The vaccine contained fragments of a molecule called her2/neu, which, perched on the surface of tumor cells, fuels the growth and proliferation of some breast cancers. Baker’s immune system treated the flood of injected her2/neu like an invading army and mounted a counterattack. Cells called CD4, acting like biological Paul Reveres, sounded the alarm, rousing white blood cells called T cells. The body’s Minutemen, they invaded Baker’s tumor, summoning reinforcements called cytotoxic (“killer”) T cells, which destroyed the tumor cells in Baker’s breast as well as her spine. Enough of the other 21 women who received the experimental vaccine against metastatic breast cancer are doing so well that its inventor, immunologist Mary (“Nora”) Disis of UW, dares to envision a future in which vaccines “control or even eliminate cancer.”



The road to a cure



After four decades of largely unfulfilled hopes—December 23 marks 40 years since President Nixon declared war on cancer—scientists have hit on a potential cure that few thought possible a few years ago: vaccines. If they succeed, cancer vaccines would revolutionize treatment. They could spell the end of chemotherapy and radiation, which can have horrific side effects, which tumor cells often become resistant to, and which often make so little difference it would be laughable were it not so tragic: last week, for instance, headlines touted two new drugs for metastatic breast cancer even though studies failed to show that they extend survival by a single day. Vaccines could make such “advances” a thing of the past. And they could make cancer as preventable, with a few jabs, as measles.

“Could” is the key word. Cancer vaccines are still being tested. Patients, doctors, and scientists know only too well that seemingly wondrous cancer therapies can flame out. But progress is accelerating. In 2010, the US Food and Drug Administration approved the first-ever tumor vaccine, called Provenge, to treat prostate cancer. Scores of other vaccines are in the pipeline. Over the summer, researchers at the University of Pennsylvania unveiled what they call a cancer “breakthrough 20 years in the making”: a vaccine against chronic lymphocytic leukemia (CLL) that has brought about remissions of up to a year and counting—and which its inventors believe can be tweaked to attack lung cancer, ovarian cancer, myeloma, and melanoma. Vaccines against pancreatic and brain cancer are also being tested. “For the first time,” says Disis, who has a $7.9 million grant from the Pentagon to develop a preventive vaccine, “clinical trials [of cancer vaccines] are demonstrating anti-tumor efficacy in numbers of patients with cancer, not just one or two unique individuals.”

First, some basics. By “cancer vaccine,” scientists mean something that will stimulate the immune system to attack malignant cells. The most direct route to that, studies suggest, is by injecting the very same molecules, called antigens, that stud the surface of cancer cells much like Lady Gaga’s hats. As with the her2/neu vaccine, that would stimulate T cells to home in on the antigens and encourage the production of killer T cells specific to cells with that antigen. It may seem odd that our bodies would attack our own cells, but by tweaking the antigens, the immune system can be spurred into attacking the tumor. Such a vaccine could be therapeutic, wiping out tumors, or, in theory, preventive, keeping tumors from forming. (Cervical cancer vaccines now on the market are strictly preventive but also unique in that they target cancer-causing viruses; most cancers aren’t caused by viruses.)

Harnessing the immune system is completely counter to how cancer is now treated, largely by chemotherapy and radiation. Both can weaken the immune system, which is why some alternative practitioners advise against them. Following that advice can be fatal. But the importance of the immune system in fighting cancer is getting new respect from the nation’s leading oncology researchers. It has also inspired a Hail Mary play from a leading advocacy group. Last year, the National Breast Cancer Coalition launched the Artemis Project with the audacious aim of eliminating breast cancer by Jan. 1, 2020. Since the most likely way to accomplish that is through vaccines, says president Fran Visco, NBCC is awarding seed grants for research on, for instance, which antigens make good targets.

NBCC has good timing: research on breast-cancer vaccines is exploding. Last week, the biotechnology firm Antigen Express, Inc., announced that 89 percent of patients who received its her2/neu vaccine were alive after 22 months, compared with 72 percent of nonvaccinated women. The company hopes to get FDA approval for a phase-three trial in 2012. Interestingly, the vaccine seems to help even women who don’t qualify for the breast-cancer drug Herceptin because their levels of her2/neu are too low. “We think 75 per cent of women with breast cancer could be candidates for the vaccine,” says president Eric von Hofe.

Vaccines have the potential to revolutionise cancer treatment because their effects do not stop with existing tumors. Cancer is notorious for its craftiness, changing the biological pathways by which cells proliferate so much that chemotherapies and even targeted molecular therapies soon stop working (that’s why even much-hyped drugs such as Avastin increase survival by, at most, a few months). Vaccines could match the cancer cells move for move. In women who receive Disis’s vaccine, after T cells destroy breast cancer cells they gobble them up and spit them out. That floods the body with the antigens that adorned the cancer cells, stimulating the immune system to target this second wave of tumor antigens. This spreading immunity creates locked-and-loaded T cells that can destroy tumor cells years after vaccination—the same kind of lifelong immunity that, say, a smallpox vaccine confers.

One final benefit of the cancer vaccine may explain why Shari Baker is alive: T cells never forget. Once the immune system has targeted a threat, be it cancer or smallpox, it keeps a reserve militia ready to attack should that threat return. In principle, that should confer immunity against breast cancer and possibly other cancers as well—forever.

The optimism surrounding cancer vaccines reflects a string of recent discoveries hinting that the immune system can vanquish cancer. Immune activity in and around a tumor—the presence of certain white blood cells—is often a harbinger that a cancer will go into remission and even vanish. A 2006 study, for instance, found that colon cancers that attract killer T cells most strongly are less likely to recur after treatment. Similarly, when early-stage lung cancer cells or some breast cancer cells are studded with T cell–attracting molecules, patients are more likely to dodge metastasis, remain in remission, and live longer. And in liver cancer and ovarian cancer, if the tumor has been invaded by T cells, patients survive longer. There is one final clue to the power of the immune system. “At least 30 percent of tumors found on mammograms would go away even if we did nothing,” breast surgeon Susan Love of UCLA told a Project Artemis workshop last spring—a tantalizing hint about the power of the immune system to eliminate cancer.

That raises the obvious question: why does anyone with a working immune system develop cancer, much less die from it? One reason is that tumor cells churn out defensive molecules that repel or destroy T cells. Several experimental therapies are trying to get around that, including an immunotherapy against metastatic melanoma that the FDA approved earlier this year. Called Yervoy, it blocks a molecule known as cytotoxic T lymphocyte antigen (CTLA4), which plays a role in impeding the immune system’s ability to fight malignant cells. “That takes the brakes off the immune system and lets it kill the cancers,” says tumor immunologist Patrick Hwu of M.D. Anderson Cancer Center, who is developing another melanoma vaccine. But Yervoy, made by Bristol-Myers Squibb and priced at $120,000, extends average survival from 6.5 months to only 10. Doing better, says Hwu, will likely require packing more immune-stimulating molecules into a vaccine.

The National Cancer Institute counts more than 150 kinds of cancer, from the almost-always survivable testicular to the fast-killing pancreatic. Those targeted by experimental vaccines include some of the deadliest, where existing therapies fall tragically short. Last month, for instance, scientists led by NCI tumor immunologist James Gulley announced promising results with a single experimental vaccine against metastatic ovarian and breast cancers. Called PANVAC, it contains genes for two antigens often found on cancer cells, carcinoembryonic antigen (CEA) and mucin1 (MUC1). The 14 ovarian-cancer patients in the study have survived an average of 15 months so far, and the 12 patients with metastatic breast cancer have survived an average of 13.7 months, just slightly better than average. But what stands out for Gulley is a patient whose metastatic breast cancer has “completely disappeared,” and who is still alive more than four years after diagnosis. “We see shrinkage of tumors that we’ve never seen before,” says Gulley. Gulley suspects the results might be even better in patients who have not received chemotherapy, which can leave the immune system “beat up.”

Vaccines might even tame pancreatic cancer. In March 2010, Bert Williams, 78, heard the worst phrase a doctor can utter: not “you have pancreatic cancer,” which Williams had been told in January, but “we didn’t get it.” The tumor was positioned such that surgically removing it could have proved fatal. Williams thought he was facing a death sentence, but his wife, Gail, found a clinical trial at the Cancer Institute of New Jersey. An oncologist there, Elizabeth Poplin, came to his bedside. We’ve been looking for you, she said: Williams had yet to receive any cancer treatments that might weaken his immune system and was otherwise healthy. He agreed to receive the experimental vaccine.

The retired advertising executive in Jackson, N.J., received the first injection in March 2010, directly into the tumor. By December, scans detected no tumors anywhere; three of five other patients with inoperable pancreatic cancer are also stable, Poplin and her colleagues reported last month. The best guess is that the vaccine, which floods the body with the tumor antigens CEA and MUC1, stimulated T cells to kill tumor cells tagged with these antigens. “The patients who were vaccinated 13 to 19 months ago are doing well for longer than I am used to,” says Poplin. “None have liver or other metastases, which is surprising because pancreatic cancer likes to spread everywhere.”

Brain cancer is as deadly as pancreatic cancer, but at least one experimental vaccine is showing promise against glioblastoma multiforme, the most common and aggressive form. It contains bits of the antigen epidermal growth factor receptor variant III, which studs brain cancer cells. In a clinical trial, 18 patients whose tumors had been surgically removed received the vaccine; median survival was 26 months, scientists at Duke University reported in 2010, compared with the usual 14. And in July, Larry Kwak of M.D. Anderson and colleagues reported that in patients given an experimental vaccine against follicular lymphoma, a form of non-Hodgkin’s lymphoma, their cancer remained in remission almost twice as long, and counting, as unvaccinated patients. Biovest International plans to seek FDA approval for the vaccine, BiovaxID, in 2012.

Would-be cancer cures have come and gone, and vaccines could fail to live up to our hopes. In many studies, patients like Shari Baker and Bert Williams are exceptions, responding almost miraculously while others derive little or no benefit. The reasons for that difference are under intense study. Some patients are too sick or weak to mount a strong immune response; this is why flu vaccines fail to protect some seniors. Also, immune therapy can take months to work, allowing tumors to grow and metastasize. And if the antigen the vaccine targets is also on healthy cells, killer T cells might go after them, too, causing autoimmune disease.

Despite these challenges, the number of believers in cancer vaccines is growing, and the money is following. Hundreds of clinical trials are recruiting patients (type “cancer and vaccine” into the search box at clinicaltrials.gov). “After many years of failure [with cancer vaccines], we’re finally getting it right,” says Kwak. Between yesterday and today, another 1,500 people in the U.S. will have died from cancer. There is no time to waste.

[pedro200]

AC:

Podes fazer novamente uma análise técnica à GNBT?
Para quando é de esperar que a MA(50) ultrapasse a MA (200)? Uma possível quebra dos máximos das ultimas semanas (0,194) atira acotação para que Patamar?

Obrigado!

Dados mais recentes:
http://www.abstracts2view.com/sabcs11/v ... u=P1-13-01

Um anúncio de uma parceria para o AE37 Phase III pode atirar a cotação para valores substancialmente superiores aos actuais!

[pedro200]

http://finance.yahoo.com/news/Generex-S ... 9.html?x=0

Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Positive interim results from Phase 2b breast cancer study of AE37 presented last month at a major scientific breast cancer conference enable update to clinical development & regulatory strategy and the potential for earlier completion of key scientific milestone.

[pedro200]

Cris (curis) em breakout mode e a gnbt aos poucos aproxima-se do máximo feito nas ultimas sessões. Se ultrapassa podemos ter um forte movimento em alta!

[francisco lopes]

mt obrigado SHEREK valeu

[sherek_JNEG]

boas tardes
alguem me pode facultar um link bonde possa ver os cofres desta menina

Vê lá se este serve?

http://www.level2stockquotes.com/real-t ... uotes.html

[Shevet]

Antigen Express Breast Cancer Vaccine Development

GNBT! Força AE37! :):)

A caminho do sonho.... Let`s begin the party!

http://www.bloomberg.com/video/83137924/

Milhões de pessoas devem ter visto a reportagem...

O anuncio de uma eventual parceria com uma grande farmaceutica para a fase III do ae37 pode fazer a cotação da GNBT subir em flecha! A generex precisa de cerca de 100 milhoes de dolares para a fase III.
Se tudo correr bem , é expectável que em 2017 a vacina esteja no mercado! (5 anos de ensaios clínicos)

Pronto Pedro, daqui a 5 anos estamos ricos, ou lisos

Ainda sou do tempo de ver a Generex a 2,80usd ehehehe

Abraço

[pedro200]

Muita animação para os lados da GNBT:

No início de 2012, está prevista uma conference call

ver em:

http://finance.yahoo.com/news/Generex-P ... 7.html?x=0

[francisco lopes]

boas tardes
alguem me pode facultar um link bonde possa ver os cofres desta menina

[pedro200]

Antigen Express Breast Cancer Vaccine Development

GNBT! Força AE37! :):)

A caminho do sonho.... Let`s begin the party!

http://www.bloomberg.com/video/83137924/

Milhões de pessoas devem ter visto a reportagem...

O anuncio de uma eventual parceria com uma grande farmaceutica para a fase III do ae37 pode fazer a cotação da GNBT subir em flecha! A generex precisa de cerca de 100 milhoes de dolares para a fase III.
Se tudo correr bem , é expectável que em 2017 a vacina esteja no mercado! (5 anos de ensaios clínicos)

[pedro200]

Antigen Express Breast Cancer Vaccine Development

GNBT! Força AE37! :):)

A caminho do sonho.... Let`s begin the party!

http://www.bloomberg.com/video/83137924/

Milhões de pessoas devem ter visto a reportagem...

[pedro200]

Publicações - Ae37 - International Journals

Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011 Sep 6. [Epub ahead of print]

Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells. J Immunol. 2011 Jul 1;187(1):316-24. Epub 2011 May 25.

Vadacca M, Valorani MG, von Hofe E, Kallinteris NL, Buzzetti R, Pozzilli P. Recognition of Ii-Key/HC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes. Horm Metab Res. 2011 Jun;43(7):483-8. Epub 2011 Apr 21.

Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines. 2011 Feb;10(2):201-10.

Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010 Nov 3;28(47):7476-82. -82. Epub 2010 Sep 19.

Perez SA, Kallinteris NL, Stratos B, Tzonis PK, Georgakopoulou K, Thanos A, Varla-Leftherioti M, Papamichail M, von Hofe E, Baxevanis CN. Results From a Phase 1 Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer. Clin Cancer Res. 2010 Jul 1;16(13):3495-506. Epub 2010 May 13.

Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. A new era in anticancer peptide vaccines. Cancer. 2010 May 1;116(9):2071-80.

Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. Vaccine. 2009 Aug 27;27(39):5393-401.

Xu M, Lu X, Sposato M, Zinckgraf JW, Wu S, von Hofe E. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. Vaccine. 2009 Jul 23;27(34):4641-7.

Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther. 2009 Jan;9(1):71-8. Review.

Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008 Jul 10;26(20):3426-33.

Van Overtvelt L, Wambre E, Maillère B, von Hofe E, Louise A, Balazuc AM, Bohle B, Ebo D, Leboulaire C, Garcia G, Moingeon P. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol. 2008 Apr 1;180(7):4514-22.

Chou CL, Mirshahidi S, Su KW, Kim A, Narayan K, Khoruzhenko S, Xu M, Sadegh-Nasseri S. Short peptide sequences mimic HLA-DM functions. Mol Immunol. 2008 Apr;45(7):1935-43.

Wambre E, Van Overtvelt L, Maillère B, Humphreys R, von Hofe E, Ferhat L, Ebo D, Moingeon P. Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspects. Int Arch Allergy Immunol. 2008 Jan;146(2):99-112.

Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, Hofe EV, Kallinteris NL, Baxevanis CN. Induction of potent CD4(+) T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer. 2007 Nov 1;121(9):2031-41.

Lu X, Wu S, Blackwell CE, Humphreys RE, von Hofe E, Xu M. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine. Immunology. 2007 Feb;120(2):207-16. Epub 2006 Nov 20.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN. Ii-Key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.

Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther. 2006 Dec;6(12):1311-21.

Kallinteris NL, Powell D, Blackwell CE, Kim M, Lu X, Wu S, Humphreys RE, Xu M, von Hofe E. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci. 2006 Jan 1;11:46-58.

Kallinteris NL, Wu S, Lu X, Humphreys RE, von Hofe E, Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother. 2005 Jul-Aug;28(4):352-8.

Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine. 2005; 18:36-8.

Wang Y, Xu M, Che M, Hofe EV, Abbas A, Kallinteris NL, Lu X, Liss ZJ, Forman JD, Hillman GG. Curative Antitumor Immune Response Is Optimal with Tumor Irradiation Followed by Genetic Induction of Major Histocompatibility Complex Class I and Class II Molecules and Suppression of Ii Protein. Hum Gene Ther. 2005; 16:187-99.

Xu M, Lu X, Kallinteris NL, Wang Y, Wu S, von Hofe E, Gulfo J, Humphreys RE, Hillman GG. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr Opin Mol Ther. 2004; 6:160-5.

Humphreys RE, Hillman GG, von Hofe E, Xu M. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell Mol Immunol. 2004 Jun;1(3):180-5.

Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing established tumors. Cancer Treat Rev. 2004;30:281-90.

Gillogly, ME, Kallinteris, NL, Xu, M, Gulfo, JV, Humphreys, RE, and Murray, JL. Ii-Key/HER-2/neu MHC class II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother. 2004;53:490-6.

Kallinteris NL, Hu H, Li Y, Lu X., Wu S, Gulfo GV, Humphreys RE, Xu M. Ii-key/ MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003;21: 4128-32.

Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Human Gene Therapy 2003;14: 763-75

Lu X, Kallinteris NL, Li J, Wu S, Li Y, Gulfo JV, Humphreys RE, Xu M. Tumor Immunotherapy by converting tumor cells to MHC Class II-positive, Ii protein-negative phenotype.

Hillman G.G., Kallinteris N.L., Li J., Wang Y., Lu X., Wu S., Wright J.L., Slos P., Gulfo J.V., Humphreys RE, Xu M. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Therapy 2003; 10: 1512-1518

Drabner B, Reineke U, Schneider-Mergener J, Humphreys RE, Hartmann S, Lucius R. Identification of T helper cell-recognized epitopes in the chitinase of the filarial nematode Onchocerca volvulus. Vaccine 2002;20:3685-94.

Xu M., Li J., Gulfo J.V., von Hofe E., Humphreys R.E. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand. J. Immunol 2001;54:39-44.

Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18:2693-7 7

Xu M, Qiu G, Jiang Z, von Hofe E, Humphreys RE. Genetic modulation of tumor antigen presentation. Trends Biotechnol. 2000;18(4):167-72.

Xu M, Jackson R, Adams S, Humphreys RE. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittel-Forschung 1999;49:791-9.

Adams S, Albericio F, Alsina J, Smith ER, Humphreys RE. Biological activity and therapeutic potential of homologs of an li peptide which regulates antigenic peptide binding to cell surface MHC class ll molecules. Arzneimittel-Forschung 1997;47:1069-77.

Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 1995;25:1693-702.